(FM) Hematología
Departamento académico
KU Leuven
Lovaina, BélgicaPublicacións en colaboración con investigadores/as de KU Leuven (49)
2024
-
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Haematologica
-
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313
-
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227
-
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235
2023
-
Alginate sulfate-nanoparticles loaded with hepatocyte growth factor and insulin-like growth factor-1 improve left ventricular repair in a porcine model of myocardial ischemia reperfusion injury
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 184, pp. 83-91
-
An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma
Leukemia and Lymphoma
-
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial
Leukemia Research, Vol. 129
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
New England Journal of Medicine, Vol. 388, Núm. 11, pp. 1002-1014
-
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269
2022
-
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Leukemia, Vol. 36, Núm. 5, pp. 1371-1376
-
Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry
Frontiers in Medicine, Vol. 9
2021
-
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)
American Journal of Hematology, Vol. 96, Núm. 1, pp. 69-79
-
Insights into therapeutic products, preclinical research models, and clinical trials in cardiac regenerative and reparative medicine: where are we now and the way ahead. Current opinion paper of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine
Cardiovascular research, Vol. 117, Núm. 6, pp. 1428-1433
-
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma
Leukemia and Lymphoma, Vol. 62, Núm. 10, pp. 2482-2491
2020
-
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1
-
Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia
Thrombosis Research, Vol. 195, pp. 139-145
-
Performance of 18F-fluorodesoxyglucose positron-emission tomography/computed tomography for cancer screening in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis
Thrombosis Research, Vol. 194, pp. 153-157
-
Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1
HEMATO
2019
-
Relationship between type of unprovoked venous thromboembolism and cancer location: An individual patient data meta-analysis
Thrombosis Research, Vol. 176, pp. 79-84